Latest Manufacturing Expansion News

Novonix Limited reports significant progress in its synthetic graphite anode materials production, benefiting from new US tariffs on Chinese imports and strategic leadership appointments. The company also secures up to US$100 million in convertible debenture funding to support expansion plans.

NOVONIX has entered a multi-tranche funding agreement with Yorkville Advisors to raise up to US$100 million through convertible debentures, supporting its Riverside facility build-out and commercial production ramp-up.

Tetratherix Limited has marked a pivotal quarter with a $25 million ASX listing, an exclusive licensing agreement with Bio Optix for ophthalmic devices, and progress on FDA regulatory submissions for its prostate spacer product.

Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase to $204 million in Q2 2025, launched its new prostate cancer imaging agent Gozellix in the U.S., and advanced key clinical trials despite an ongoing SEC inquiry.

DroneShield is investing $13 million to significantly expand its R&D and manufacturing footprint, aiming to boost annual production capacity nearly fivefold by the end of 2026.

Tissue Repair Limited has secured major distribution partnerships in Australia, New Zealand, and Thailand for its TR Pro+® product line, marking a pivotal shift from development to commercialisation. The company is also scaling up manufacturing and advancing regulatory approvals to support its global expansion ambitions.

AML3D has received a pivotal Letter of Intent from the US Navy, outlining plans for additive manufacturing collaboration and significant demand growth through 2030.

Mayfield Group Holdings has agreed to acquire BE Switchcraft for $7 million, enhancing its manufacturing footprint and product range in energy management and automation. The deal positions Mayfield as a stronger player in Australia's electrical infrastructure market.

Elsight Limited has expanded its supply agreement with a European defence drone OEM to a total of US$9.63 million for 2025, positioning the company for profitability and cash flow break-even this year.

OncoSil Medical has launched a $8.7 million capital raising via a Share Purchase Plan and Placement, seeking shareholder approval for options issuance and a 400:1 share consolidation.

FFI Holdings Limited has announced a pro-rata non-renounceable entitlement offer priced at $3.50 per share, aiming to raise approximately $11 million to support its food manufacturing growth and property investments. The offer closes on 17 June 2025 and is open to eligible shareholders in Australia and New Zealand.

EBR Systems has won FDA approval for its pioneering leadless WiSE CRT System, setting the stage for a phased US commercial rollout. The company also secured key Medicare reimbursement pathways and expanded manufacturing capacity, though financial sustainability remains a concern.